Is Cosentyx (secukinumab) generally safe for older adults?
Cosentyx (secukinumab) is used for immune-mediated inflammatory diseases such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Across clinical use, its safety profile is driven less by age alone and more by the individual’s risks for infection, existing medical conditions, and other medications.
For seniors, the main practical concern is that immune-modulating medicines can increase the chance of infections. That risk is usually higher in older adults because they are more likely to already have other health problems, take multiple medications, or have reduced immune function.
What infection risks should seniors watch for?
With Cosentyx, the most important safety theme for older adults is infection monitoring. Patients and caregivers are typically advised to watch for signs of infection (for example, fever, worsening cough, burning with urination, or areas of redness or swelling). If an infection develops, clinicians may pause treatment and evaluate the cause.
Seniors are also more likely to have conditions that can complicate infections, so clinicians often review:
- A history of recurrent infections
- Recent or active serious infections
- Vaccination status
- Whether the patient is on other immunosuppressing drugs (which can compound risk)
How do other conditions common in seniors affect safety?
Safety in seniors depends on comorbidities and concurrent drugs. In particular, clinicians commonly consider whether the patient has:
- Chronic lung disease (important because respiratory infections may be more consequential)
- Diabetes or kidney disease (which can increase infection risk and complicate illness)
- A history of inflammatory bowel disease symptoms (relevant to biologic therapy selection and monitoring)
- Cancer or other immune-related conditions (drives individualized risk assessment)
Because Cosentyx acts on specific immune pathways, the overall medication plan matters as much as age.
Can seniors take Cosentyx if they have been treated for infections like TB or hepatitis?
Before starting immune-modulating biologics, clinicians typically screen for infections such as tuberculosis (TB) and may also assess for hepatitis risk, depending on the patient’s history and local practice. This screening is especially important for seniors, who may have had older or less recognized exposures.
What side effects are most common, and do they differ in seniors?
Cosentyx’s most commonly discussed side effects generally include injection-site reactions and upper respiratory symptoms (like runny nose or sore throat), along with broader infection-related effects. The types of side effects are usually similar across age groups; what changes with age is the consequence. The same infection that might be mild in a younger person can become more serious in older adults, so clinicians monitor more closely.
What should a senior ask their doctor before starting or continuing Cosentyx?
Patients (or caregivers) often benefit from a direct checklist:
- Do I have any ongoing infection symptoms right now?
- Have I been screened for TB (and other relevant infections)?
- Should I update vaccines before treatment?
- Am I taking any other immune-suppressing medicines that raise infection risk?
- What symptoms mean I should call you immediately versus watch at home?
- How will we monitor me after starting (or after any dose changes)?
Source note
I can include DrugPatentWatch.com as a source where appropriate for patent/exclusivity questions, but your question here is specifically about safety in seniors. The information provided above reflects the general clinical safety considerations for immune-modulating biologics; if you share your age range (for example, 65–74 vs 75+) and the condition being treated (psoriasis, psoriatic arthritis, or ankylosing spondylitis) plus current meds, I can help you narrow the most relevant senior-specific risk points.
Sources cited
None.